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Introduction
The Bombesin receptor family is a well-known important 
target for diagnostic and therapeutic applications. It consists 
of four receptor subtypes including the neuromedin B 
receptor (BB1), the gastrin-releasing peptide receptor 
(GRP-R, BB2), the orphan receptor subtype (BB3), and 
the amphibian receptor (BB4) (Battey et al., 1991; Fathi 
et al., 1993; Nagalla et al., 1995; Wada et al., 1991). The 
first two are widely diffused in normal tissues and on cells 
of several human tumors: for example, the GRP-R has 
been found overexpressed by tumor cell lines of ovarian 
cancers, breast cancers and prostate cancers (Markwalder 
& Reubi, 1999; Gugger & Reubi, 1999; Fleischmann et al., 
2007), while BB1 has been found overexpressed in ileal 
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Purpose: This study addresses novel peptide modified liposomal doxorubicin to specifically target tissues 
overexpressing bombesin (BN) receptors.
Methods: DOTA-(AEEA)2-peptides containing the [7–14]bombesin and the new BN-AA1 sequence have been 
synthesized to compare their binding properties and in serum stabilities. The amphiphilic peptide derivative (MonY-
BN-AA1) containing BN-AA1, a hydrophobic moiety, polyethylenglycole (PEG), and diethylenetriaminepentaacetate 
(DTPA), has been synthesized. Liposomes have been obtained by mixing of MonY-BN-AA1 with 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC).
Results: Both 111In labeled peptide derivatives present nanomolar Kd to PC-3 cells. 177Lu labeled peptide DOTA-
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the therapeutic efficacy of DSPC/MonY-BN-AA1/Dox in comparison to DSPC/MonY-BN/Dox, were performed in PC-3 
xenograft bearing mice. Both formulations showed similar tumor growth inhibition (TGI) compared to control animals 
treated with non-targeted DSPC/Dox liposomes or saline solution. For DSPC/MonY-BN-AA1/Dox the maximum effect 
was observed 19 days after treatment.
Conclusions: DSPC/MonY-BN-AA1/Dox nanovectors confirm the ability to selectively target and provide therapeutic 
efficacy in mice. The lack of receptor activation and possible acute biological side effects provided by using the AA1 
antagonist bombesin sequence should provide safe working conditions for further development of this class of drug 
delivery vehicles.
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carcinoids. They bind the mammalian bombesin peptides: 
gastrin-releasing peptide (GRP) and neuromedin B 
(NMB). Both peptides demonstrate a broad spectrum of 
pharmacological and biological responses and affect the 
growth and/or differentiation of a number of important 
human tumors including colon, prostate, lung and some 
gynecologic cancers.
The fourteen-residue Bombesin peptide (BN), its 
eight-residues C-terminal peptide sequence ([7–14]BN), 
and many other Bombesin analogues acting as agonist 
or antagonists, have been modified to selectively carry 
diagnostic or therapeutic agents to their receptors. Many 
studies demonstrate that bombesin fragment [7–14]
BN modified on the N-terminus with radioactive metal 
complexes of 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA) or diethylenetriaminepenta 
acetic acid (DTPA) preserves its affinity for these recep-
tors and several BN analogues containing aliphatic or 
amino acidic linkers placed between the BN peptide and 
the radioactive metal complex, display selective uptake 
on cells overexpressing GRP receptors, with IC
50
 values 
in the nanomolar range, in in vitro experiments and in 
in vivo studies (Smith et al., 2005; Rogers et al., 2003; 
Parry et al., 2007).
As already reported for other neuroendocrine pep-
tides (CCK8, RGD, Octreotide), bombesin peptides can 
be not only covalently bound to a diagnostic or a thera-
peutic agent, but also coupled to nanovectors, such as 
nanoparticles or liposomes, to deliver contrast agents 
(Accardo et al., 2010; Hosta-Rigau et al., 2010; Lee et al., 
2010; Mendoza-Sánchez et al., 2010; Martin et al., 2009) 
and/or cytotoxic drugs (Chanda et al., 2010). In order to 
achieve this last goal, the bioactive peptide must main-
tain its high affinity for the target receptor when exposed 
on the external surface of the nanovector and should 
remain stable in the blood stream for the prolonged 
time in which the cargo vehicle remains in circulation. 
Moreover, to avoid possible side-effects induced by the 
injection of large quantities of nanovectors, and conse-
quently bioactive peptides, it is desirable that the bioac-
tive peptide behave as an antagonist in order to avoid 
activation of biological pathways (Chan et al., 2011; Zhu 
& Chen, 2004).
With the aim of developing new target selective ther-
anostic agents against cells overexpressing bombesin 
receptors, a new class of liposomes, based on a mix of 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) 
phospholipid with a new synthetic amphiphilic mono-
mer, MonY-BN, and encapsulating the cytotoxic drug 
doxorubicin (Dox), were recently developed (Accardo 
et al., 2012). MonY-BN consists on a monomer contain-
ing the [7–14]Bombesin peptide fragment, the DTPA che-
lating agent, the hydrophobic moiety with two C18 alkyl 
chains and PEG spacers all in a single molecule (Accardo 
et al., 2012). This system showed encouraging results in 
vivo, leading to a significant tumor growth inhibition, 
compared to “conventional” liposomes encapsulating 
Dox (60% vs 36%), in PC-3 xenograft-bearing mice.
In the current manuscript, we attempt to enhance 
“performance” of the nanovectors by utilizing a modi-
fied sequence of the [7–14]Bombesin peptide that should 
improve the overall properties of the agent. The new pep-
tide sequence that has been introduced into the MonY 
monomer, should afford higher serum stability, main-
tain high receptor affinity and is expected to behave as 
a bombesin antagonist, thus providing more desirable in 
vivo properties of the entire nanovector.
Methods
Instrumentation
Preparative HPLCs were carried out on a LC8 Shimadzu 
HPLC system (Shimadzu Corporation, Kyoto, Japan) 
equipped with a UV lambda-Max Model 481 detector. 
Crude products were eluted with H
2
O/0.1% trifluoroace-
tic acid (TFA) (A) and CH3CN/0.1% TFA (B) at 20 mL/
min flow rate. Purifications of peptide conjugates were 
performed by using. Purifications of lipophilic peptides 
were performed by using a Phenomenex (Torrance, CA) 
C4 (300 Ǻ, 250 × 21.20 mm, 5 µ) column eluted with an 
H
2
O/0.1% trifluoroacetic acid (TFA) (A) and CH
3
CN/0.1% 
TFA (B) from 20% to 95% over 25 min at 20 mL/min flow 
rate. LC–MS analyses were performed by using Finnigan 
Surveyor MSQ single quadrupole electrospray ionization 
(Finnigan/Thermo Electron Corporation San Jose, CA). 
UV measurements were performed on a UV-vis Jasco 
V-5505 spectrophotometer equipped with a Jasco ETC-
505T Peltier temperature controller with a 1-cm quartz 
cuvette (Hellma).
Pharmaceuticals and reagents
Protected Nα-Fmoc-amino acid derivatives, cou-
pling reagents and Rink amide MBHA resin were 
purchased from Calbio-chem-Novabiochem 
(Laufelfingen, Switzerland). The Fmoc-21-amino-
4,7,10,13,16,19-hexaoxaheneicosanoic acid (Fmoc-
Ahoh-OH) and Fmoc-8-amino-3,6-dioxaoctanoic acid 
(Fmoc-AdOO-OH) were purchased from Neosystem 
(Strasbourg, France). N,N-dioctadecylsuccinamic acid 
was prepared according to the experimental proce-
dure reported in literature (Schmitt & Dietrich, 2004). 
α-(9-Fluorenylmethyloxycarbonyl) amino-ω-carboxy 
poly(ethylene glycol) (Fmoc-NH-Peg27-COOH) was 
purchased by Iris Biotech GmbH (Marktredwitz, 
Germany). DOTA(OtBu)3-OH (1,4,7,10-tetraazacy-
clododecane-1,4,7,10-tetraacetate tert-butyl ester)) and 
DTPA(OtBu)4-OH (diethylenetriaminepentaacetate 
tetra-tert-butyl ester) was purchased from Chematech 
(Dijon, France). Citrate acid, sodium citrate, sodium 
chloride and Doxorubicin were obtained from Sigma 
Chemical Co. (St. Louis Mo, USA). All other chemicals 
were commercially available by Sigma-Aldrich, Fluka 
(Bucks, Switzerland) or LabScan (Stillorgan, Dublin, 
Ireland) and were used as received unless otherwise 
stated. 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC) was purchased from Lipoid GmbH (Cam, 
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Switzerland). All solutions were prepared by weight 
using doubly distilled water.
Peptide derivatives synthesis
DOTA-(AEEA)
2
-BN and DOTA-(AEEA)
2
-BN-AA1
Peptide syntheses were carried out in solid-phase under 
standard Fmoc strategy, by using 433A Applied Biosystems 
automatic synthesizer. Rink-amide MBHA resin (0.78 
mmol/g, 0.5 mmol scale, 0.640 g) was used. The elongations 
of the bombesin peptides were achieved by sequential 
addition of Fmoc-AA-OH with benzotriazol-1-yl-oxy-
tripyrrolidinophosphonium hexafluorophosphate/1-
hydroxy-1,2,3-benzotriazole/N,N-diisopropylethylamine 
(PyBOP/HOBt/DIPEA) (1:1:2) as coupling reagents, in 
N,N-dimethylformamide (DMF) in pre-activation mode. 
The mixture was stirred for 1 h and after filtration. All cou-
plings were performed twice for 1 h, by using an excess of 
4 equivalents for the single amino acid derivative. Fmoc 
deprotections were obtained by 30% solution of piperidine 
in DMF. When the bombesin sequences were complete, 
the Fmoc N-terminal protecting group was removed and 
two residues of Fmoc-AdOO-OH were added. An excess of 
2 equivalents of Fmoc-AdOO-OH, PyBop and HOBt and 4 
equivalents of DIPEA were dissolved in DMF and added 
to the manual vessel. When the linkers were coupled on 
the peptide chain, the DOTA-tetraester chelating agent 
was linked, through its free carboxyl function. This cou-
pling step was performed using 2.0 equivalents of DTPA 
tetraester and HATU, and 4 equivalents of DIPEA in DMF 
as solvent. The coupling time, compared with the classical 
solid phase peptide synthesis protocol, was increased up 
to 2 h. For deprotection and cleavage, the fully protected 
resins were treated with a mixture of trifluoroacetic acid 
(TFA), triisopropylsilane (TIS), and water in the TFA/TIS/
H
2
O 95/2.5/2.5 ratio, and the free product precipitated at 
0°C by adding water drop wise. Purification of the crude 
mixture was carried out by RP-HPLC (λ = 280 nm). The 
final product was recovered at purity higher than 95% and 
with a final yields of 50%. Mass spectra confirm the prod-
uct identity (see Table 1).
DOTA-(AEEA)
2
-BN: Rt =12.91 MW: 1613 amu MS 
(ESI+): m/z (%): [M+2H+]/2 = 807.5 amu
DOTA-(AEEA)
2
-BN-AA1: Rt = 13.13 MW: 1976 amu MS 
(ESI+): m/z (%): [M+2H+]/2 = 989 amu
Synthesis of (C
18
H
37
)
2
NCO(CH
2
)
2
CO-Peg27-Lys(DTPA)-
Ahoh-DPhe-Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-
Amide; (MonY-BN-AA1)
Synthesis of MonY-BN-AA1 was carried out in solid-
phase under standard Fmoc/tBu strategy, as  previously 
described (Chang & White, 2000) for the parent MonY-BN 
monomer. Rink-amide MBHA resin (0.78 mmol/g, 0.5 
mmol scale, 0.640 g) was used as solid support. Peptide 
derivative was cleaved from the resin with TFA (5 mL) 
containing 2.5% (v/v) water and 2.0% (v/v) tri-isopro-
pylsylane (TIS) as a scavenger at room temperature for 
2 h. Free peptide was precipitated in cold ethyl ether 
and lyophilized from a 50% H
2
O/CH
3
CN solution. Crude 
peptide was purified by reversed phase HPLC and each 
fraction was characterized by LC–MS analysis.
(C
18
H
37
)
2
NCO(CH
2
)
2
CO-Peg27-Lys(DTPA)-Ahoh-
DPhe-Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-Amide; 
MonY-BN-AA1: Rt = 25.2 min; (MW = 3870) [M+3H+]/3 = 
1291 amu and [M+4H+]/4 = 968.5 amu.
Serum stability
177Lu-DOTA-peptide conjugates were prepared by dis-
solving 10 µg of peptide in 250 µL of sodium acetate buf-
fer (0.4 M, pH 5.0) and incubating the peptide solution 
with 177LuCl
3
 (74–185 MBq) for 30 min at 95°C. Quality 
control was performed using radio-HPLC. To 1.0 mL of 
freshly prepared human serum, previously equilibrated 
in a 5% CO
2
 environment at 37°C, we added 0.6 nmol of 
the 177Lu-labeled peptide. The mixture was incubated in 
a 5% CO
2
, 37°C environment. At different time points, 
100 µL aliquots (in triplicate) were removed and treated 
with 200 µL of EtOH to precipitate serum proteins. 
Samples were then centrifuged for 15 min at 500 rpm. 
50 µL of supernatant were removed for activity count-
ing in a γ-well counter, the sediment was washed twice 
with 1 mL of EtOH and counted, and the activity in the 
supernatant was compared with the activity in the pel-
let to give the percentage of peptides not bound to pro-
teins or radiometal transferred to serum proteins. The 
supernatant was analyzed by radio-HPLC (eluents: A = 
0.1% trifluoroacetic acid in water and B = acetonitrile; 
gradient: 0–25 min 95–50% B) to determine the relative 
amount of intact peptide and its metabolites in serum. 
The half-life was calculated fitting a first order reaction to 
the experimental data (Equation 1) using Prism software 
(GraphPad Software Inc.).
[ ]A e k t= − 1 (1)
Saturation binding experiments
The peptide conjugates were studied in vitro by per-
forming cellular binding-saturation experiments using 
increasing concentrations of the 111In-DOTA-peptide 
ranging from 0.5 to 50 nM. Confluent PC-3 cells were 
seeded in six-well plates (~1.0·106 cells) 24 h before start-
ing the experiments. For blocking experiments excess 
Table 1. LC-MS data, dissociation constant (K
d
), apparent number of binding sites per cells (B
max
) and half-life of DOTA-(AEEA)
2
-BN and 
DOTA-(AEEA)
2
-BN-AA1 peptide conjugates. 
Peptide conjugates Rt/min Mw/amu K
d
/nM B
max
 (binding sites/cell) half-life/h
DOTA-(AEEA)
2
-BN 12.91 1613 3.30 ± 0.39 2.45 × 05 ± 10.07 15.5 ± 2.1
DOTA-(AEEA)
2
-BN-AA1 13.13 1796 5.91 ± 0.57 3.52 × 05 ± 10.10 414.1 ± 39.4
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(1000 fold) of cold peptide was used. For each radioli-
gand, triplicates were prepared for every concentration, 
for both total binding and nonspecific binding. Before 
adding the radioligands to the wells, the plates were 
placed on ice for 30 min. After adding the radioligands 
and the blocking for nonspecific binding, the plates were 
incubated for 1 h at 4°C. Afterwards, the binding buffer 
was removed and the cells were washed twice with ice-
cold phosphate-buffered saline (PBS, pH 7.4). Cell bound 
radioactivity was subsequently recovered by trypsiniza-
tion of the wells. Radioactivity in the bound and free 
fractions was determined with a Wizard gamma-counter 
(Wallac, Turku, Finland). Specific binding was calculated 
by subtracting nonspecific from total binding at each 
concentration of radioligand. Affinity (K
d
) and apparent 
number of binding sites per cell (B
max
) were calculated 
from Scatchard plots using Prism software (GraphPad 
Software Inc.)
Liposomes preparation
The liposomes were prepared by a modified reverse-
phase evaporation technique, as previous reported 
(Accardo et al., 2012). Briefly, the lipid mixture composed 
of DSPC or DSPC/MonY-BN-AA1 (1:0.03 molar ratio) was 
dissolved in a mixture chloroform/methanol (2:1 v/v). 
The organic solution was added to a 50 mL round-bottom 
flask, and the solvent was removed under reduced pres-
sure by a rotary evaporator under nitrogen atmosphere. 
The resulting lipid film was dissolved in 3 mL diethyl ether 
and the solution was emulsified, by sonication for 30 min 
in a bath-type sonicator (Branson 3510, Danbury, USA), 
with 1 mL of citrate buffer at pH 4,0 (150 mM of citric 
acid; 150 mM of sodium citrate). The resulting emulsion 
was then placed on the rotary evaporator (Laborota 4010 
digital, Heidolph, Schwabach, Germany) and the organic 
solvent was removed under reduced pressure at 30°C in 
nitrogen atmosphere. When viscous gel was obtained, the 
vacuum was broken and the gel was vortexed for about 
1 min. Then, the dispersion was placed at rotary evapora-
tor under vacuum for about 15 min. Then, 1 mL of citrate 
buffer was added and the suspension was heated at 65°C 
for 30 min. The resulting liposome suspension was then 
extruded at 65°C, using a thermobarrel extruder system 
(Northern Lipids Inc., Vancouver, BC, Canada), passing 
repeatedly the suspension under nitrogen through poly-
carbonate membrane (Nucleopore Track Membrane 
25 mm, Whatman, Brentford, UK) with 0.1 µm pore size. 
The external buffer was removed by ultracentrifugation 
(Optima Max E, Beckman Coulter, USA; rotor TLA 120.2) 
at 80.000 rpm, at 4°C for 30 min, and the liposomes were 
resuspended with 1 mL of HBS buffer at pH 7.4 (20 mM of 
HEPES; 150 mM of sodium chloride), giving a suspension 
with a total lipid concentration 0.010 M. The actual phos-
pholipid concentration of liposomes was determined by 
the Stewart’s assay (Stewart, 1980). Briefly, an aliquot of 
the liposome suspension was added to a two-phase sys-
tem, consisting of an aqueous ammonium ferrothiocya-
nate solution (0.1 N) and chloroform. The concentration 
of DSPC was obtained by measuring the absorbance at 
485 nm into the organic layer.
Radiolabeling of liposomes and in vitro binding 
studies
Radiolabeling and in vitro binding assays of the targeted 
liposomes (DSPC/MonY-BN and DSPC/MonY-BN-AA1), 
of untargeted liposomes (DSPC/(C18)
2
DTPA (0.1%)) 
and of targeted liposomes (DSPC/MonY-BN and DSPC/
MonY-BN-AA1) in presence of a 1000 fold excess of cold 
peptide, at a final concentration of 2 × 10−4 M and incu-
bated for 1 h at 4°C and at 37°C, were performed a previ-
ously described (Accardo et al., 2011). Quality control of 
labeling was obtained by gel filtration on Sephadex G-50 
pre-packed columns (Pharmacia Biotech, Piscataway, 
NJ) (Accardo et al., 2008). Cell bound radioactivity was 
recovered by trypsinization of the wells. Radioactivity 
in the bound and free fractions was determined with a 
Wizard gamma-counter (Wallac, Turku, Finland).
Doxorubicin encapsulation into liposomes
Dox was encapsulated into liposomes by remote loading 
as already described for the parent liposome formulation 
DSPC/MonY-BN (Accardo et al., 2011). Briefly, the lipo-
somes suspension were combined with the Doxorubicin 
at a drug/lipid ratio of 0.2 (w/w), and then incubated 
at 65°C for 1 h. The amount of encapsulated Dox was 
determined as follows: 1 mL of liposome dispersion was 
ultracentrifugated at 80.000 rpm at 4°C for 30 min, the 
supernatant was carefully removed and Dox concentra-
tion was determined by UV/Visible spectrophotometer 
at 480 nm. The results have been expressed as encapsula-
tion efficiency, calculated as [(TSDox – ASDox)/TSDox] 
× 100, where TSDox is the theoretical Dox in the super-
natant before encapsulation and ASDox is the actual Dox 
concentration in the supernatant. All liposome prepara-
tions were stored at 4°C. Each formulation was prepared 
in triplicate.
Liposomes characterization
The mean diameter of the liposomes was determined 
at 20°C by photon correlation spectroscopy (PCS) (N5, 
Beckman Coulter, Miami, USA). Each sample was diluted 
in deionizer/filtered (0.22 µm pore size, polycarbonate 
filters, MF-Millipore, Microglass Heim, Italy) water and 
analyzed with detector at 90° angle. As measure of the 
particle size distribution, polydispersity index (P.I.) was 
used. For each batch, mean diameter and size distribu-
tion were the mean of three measures. For each formula-
tion, the mean diameter and P.I. were calculated as the 
mean of three different batches. The zeta-potential (ζ) of 
the liposomes surface was measured in water by means 
of a Zetasizer Nano Z (Malvern, UK). Data of ζ were col-
lected as the average of 20 measurements.
Cytotoxicity assays
Cytotoxicity of DSPC/MonY-BN-8(3%)/Dox and DSPC/
Dox and free Dox was determined as already described 
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for the parent compound DSPC/MonY-BN/Dox (Accardo 
et al., 2012). The colorimetric MTS (3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium, inner salt) assay was used. 
Briefly, 8000 PC-3 cells/well were plated in 96-well plates 
and incubated overnight to allow cell attachment. The 
culture medium was removed and cells were incubated 
with free Dox and liposomes containing 100 and 300 ng/
mL Dox. After 8 h the medium was removed and the cells 
were incubated for an additional 72 h in fresh medium. 
Plates were then incubated with 20 µL of MTS in 100 
µL of culture medium. Finally, 25 µL of 10% SDS were 
added to all wells to stop of the reaction and mixed thor-
oughly. The absorbance was measured with a BioRad 680 
microliter plate reader (BioRad, BioRad, Corston, UK) at 
a wavelength of 490 nm. Cells incubated with Dox-free 
liposomes were used as control. Viability was expressed 
as percentage of control (mean ± SEM) for each condi-
tion. The experiment was performed at least 3 times with 
triplicate wells. IC
50
 values for each treatment conditions 
were calculated graphically.
In vivo experiments
Female BALB/c nude mice (6 week old; Harlan Nossan, 
Italy) were injected subcutaneously (sc.) on the flank 
with 2–3 × 106 PC-3 cells, suspended in PBS with 0.1% 
glucose and mixed with equal volume of Matrigel TM (BD 
Biosciences, Bedford), prepared as described above. All 
procedures were performed within a laminar air-flow 
cabinet using aseptic technique. Tumor size was mea-
sured each second day, starting 28 days following cell 
inoculation, by the mean of a digital caliper (2 Biological 
Instruments, Besozzo, VA, Italy) and evaluated as tumor 
volume (mm3) calculated by the following formula: long 
diameter (D) × short diameter (d)2/2. Approximately 5 
weeks after cell implantation, when tumors reached an 
average volume of 170/200 mm3, mice were randomly 
distributed into three groups (n = 5) and intravenously 
(lateral tail vein) administered with the following ster-
ile formulations: saline buffer (control), DSPC/MonY-
BN-AA1/Dox (10 mg/kg), DSPC/MonY-BN/Dox (10 mg/
kg) and DSPC/Dox (10 mg/kg). Drug dosage was adjusted 
with sterile HBS according to mean body weight for each 
group. After dosing, mice were also monitored, twice a 
week, for body weight to assess non-specific drug toxic-
ity. General animal health condition was also evaluated 
to detect potential side effects, including food and water 
withdrawal, impaired movement, body weight loss or 
behavioral changes. Procedures involving animals and 
their care were in conformity with institutional guide-
lines that comply with national and international laws 
and policies. Implanted tumor size was evaluated 1 week 
following treatments and then every 4 days for the fol-
lowing 16 days. The experiment was ended once control 
tumors reached a volume close to 1,000 mm3 and before 
any sign of deteriorating health. Tumor growth curves, 
obtained by plotting tumor volume (mm3) versus time 
after treatment (days), were generated for the different 
experimental groups. All animal experiments complied 
with the Italian D.L. n. 116 of 27 January 1992 and asso-
ciate guidelines in the European Community Council 
Directive of 24 November 1986 (86/609/ECC).
Results and discussion
Peptide selection
In order to compare stability and binding properties of 
a bombesin analog sequence with the [7–14] wild type 
bombesin peptide, we have synthesized two peptide 
derivatives with the general formula DOTA-(AEEA)
2
-
peptide in which the DOTA chelating agent has been 
introduced on the N-terminal end of bombesin like pep-
tide and two amino-ethoxy-ethoxy-acetic acid (AEEA) 
residues have been used to space the active sequence 
from the DOTA chelating agent. As reported in Figure 1, 
DOTA-(AEEA)
2
-BN contains the wild type sequence of 
[7–14]BN, i.e. the same peptide sequence we already 
used in MonY-BN, while DOTA-(AEEA)
2
-BN-AA1 con-
tains a modified bombesin sequence (BN-AA1) that 
should yield the desired high serum stability, high recep-
tor affinity and should act as a bombesin antagonist. The 
peptide sequence (BN-AA1) has been chosen following 
the indications reported by Maecke et al (Mansi et al., 
2009, 2011; Abiraj et al., 2011; Llinares et al., 1999) and by 
Ametamey et al (Höhne et al., 2008). In the new peptide 
sequence the Leu13-Met14 C-terminal sequence has been 
replaced by Sta13-Leu14 for stabilization against amino-
peptidase and N-methyl-glycine has been inserted in 
place of natural glycine in order to reinforce the Val-Gly 
bond that could be sensitive to carnitine enzyme in vivo. 
Moreover, as previously reported (Mansi et al., 2009) 
the replacement of Leu13 with the Sta13 residue provides 
antagonist properties to the peptide. Finally, the D-Phe 
residue on the N-terminal end of the bioactive sequence 
should increase binding and stability.
Binding and stability studies of peptide derivatives
The DOTA-(AEEA)
2
-peptides were synthesized by Fmoc/
tBu chemistry according to standard solid phase peptide 
synthesis protocols, using Rink-amide MBHA resin as 
polymeric support (Chang & White, 2000). Both peptide 
conjugates were collected in good yields after HPLC-RP 
purification. Analytical liquid chromatography–mass 
spectrometry (LC-MS) data confirmed the compound 
identities and their high purity (see Figure 1).
The peptides were labeled with 177LuCl
3
 at specific 
activities of 31 GBqµmol−1 with a labeling yield of >98%. 
After incubation in human serum at 37°C up to 72 h, the 
amount of intact peptide was determined using radio-
HPLC analysis. The peptide DOTA-(AEEA)
2
-BN-AA1 is 
the most stable with a half-life of 414.1 ± 39.4 h, while 
the wild-type [7–14]bombesin peptide derivative, 
DOTA-(AEEA)
2
-BN, show a half-life of only 15.5 ± 2.1 h 
(Figure 2a). As concerns the binding properties to GRP 
receptors overexpressed by PC3 cells, the two pep-
tide derivatives labeled with 111In showed a similar 
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behavior with K
d
 values of 3.30 ± 0.39 nM (mean ± SD) 
and 5.91 ± 0.57 nM for DOTA-(AEEA)
2
-BN and DOTA-
(AEEA)
2
-BN-AA1, respectively; and B
max
 values of 
(2.45 ± 0.07)·105 and (3.52 ± 0.10)·105 binding sites/cell 
(Figure 2b).
Liposome formulation and characterization
The new peptide derivative MonY-BN-AA1 (Figure 3) 
containing the Bombesin analog peptide BN-AA1, the 
DTPA chelating agent, the hydrophobic moiety with two 
C18 alkyl chains, and PEG spacers in a single molecule 
Figure 1. (A) Schematic representation of DOTA-(AEEA)
2
-BN and DOTA-(AEEA)
2
-BN-AA1 peptide conjugates; (B) and (C) HPLC 
chromatogram and ESI mass spectra of DOTA-(AEEA)
2
-BN-AA1 peptide, respectively.
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was synthesized in order to formulate new liposomes 
with expected improved properties compared to the 
DSPC/MonY-BN liposomes recently developed (Accardo 
et al., 2012).
The chemical synthesis of MonY-BN-AA1 was 
performed in solid-phase by using standard 
solid-phase-peptide-synthesis (SPPS) procedures based 
on Fmoc/tBu chemistry using rink-amide resin as poly-
meric support. The peptide derivative was cleaved from 
the resin and free peptide precipitated in cold ethyl ether 
and lyophilized. The crude compound was purified by 
reversed phase HPLC and characterized by LC–MS anal-
ysis and Maldi-TOF.
Liposomes composed of DSPC/MonY-BN-AA1 
(7.66 mg DSPC, 1.16 mg MonY-BN-AA1; 97/3 molar 
ratio) were prepared as already reported for the par-
ent supramolecular aggregate based on DSPC and 
MonY-BN (Accardo et al., 2012), and fully character-
ized. HBS buffer solution (1.0 mL) was used with a 
final lipid concentration 0.010 M. The mean diameter, 
the polydispersity index (P.I.), and zeta potential (ζ) 
of the mixed liposomes DSPC/MonY-BN-AA1 (97/3 
molar ratio) are 136.3 ± 42.4 nm, 0.20 ± 0.05, and −12.8, 
respectively, as reported in Table 2. Liposome stability 
was investigated by DLS measurements: stock solutions 
of mixed liposomes DSPC/MonY-BN-AA1 (97/3 molar 
ratio) at lipid concentration 0.010 M were prepared in 
pure water and in water buffered at pH 7.4 containing 
0.9% w/w NaCl and stored at 4°C and 37°C. Mean diam-
eter and polydispersity index were measured every 7 
days. All scattering intensity curves are superimposed 
indicating that any variation of size and P.I. occur in 1 
month.
Doxorubicin was encapsulated in the targeted 
and untargeted liposomes by the remote loading 
method. The drug/lipid (w/w) ratio used was of 0.2. 
The experimental conditions, namely the buffer used 
in the internal aqueous phase, the incubation time as 
well as the incubation temperature, have been previ-
ously described for the loading of DSPC/MonY-BN 
(Accardo et al., 2012). A drug-loading content >90% 
was achieved preparing liposomes in citrate buffer 
and incubating them with the drug for 1 h at 65°C. As 
expected, the loading of doxorubicin in liposomes did 
not alter morphology and size of the nanovectors (data 
not shown).
Figure 2. (A) In vitro serum stability of 177Lu-DOTA-(AEEA)
2
-BN 
and 771Lu-DOTA-(AEEA)
2
-BN-AA1 at 37°C; (B) saturation binding 
curves of 111In-DOTA-(AEEA)
2
-BN and 111In-DOTA-(AEEA)
2
-BN-AA1 
on PC-3 cells at 4°C.
Figure 3. Schematic representation of DSPC phospholipid and MonY-Peg27(DTPA)-BN-AA1 (MonY-BN-AA1) amphiphilic molecule and 
liposomal structure obtained by mixing DSPC/MonY-BN-AA1 in 97/3 molar ratio. The peptide sequence of bombesin analog is reported 
using the three-letter amino acid code.
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In vitro studies
Effective binding capability of liposomes decorated with 
BN and BN-AA1 peptide sequences was confirmed by 
in vitro nuclear medicine studies in PC-3 cell lines at 
4°C and 37°C. The labeling of liposomes was achieved by 
adding trace amounts of 111InCl
3
. Nude DSPC liposomes, 
containing very low amount of 111-In-DTPA(C18)
2
 
(0.1%), were used as negative control system. A competi-
tion assay for BN-AA1 liposomes in presence of an excess 
of cold peptide was also performed to assess receptor 
selectivity. Radiolabeling of the liposomes was >95% at 
2 × 10−4 M concentration as confirmed by gel filtration. 
From the inspection of Figure 4a, both mixed formula-
tions containing BN and BN-AA1 peptide sequences 
(DSPC/MonY-BN and DSPC/MonY-BN-AA1) shown a 
preferential binding to PC-3 cells (2.7 ± 0.3, 3.0 ± 0.3 at 
37°C) with respect to the pure DSPC liposomes (1.4 ± 0.2 
at 37°C). Moreover, the competition assay between 
DSPC/MonY-BN-AA1 and cold peptide (binding data at 
0.8 ± 0.3, at 37°C), confirming receptor selectivity. These 
results confirm that binding activity of both peptide 
sequences towards cells over-expressing GRP receptors 
is conserved when the peptides are allocated on the 
external liposomal surface. As expected, comparable val-
ues of binding activity have been found for the wild type 
sequence of [7–14] BN and for the antagonist sequence.
Cytotoxicity assays of doxorubicin liposomes
The cytotoxic effect of DSPC/MonY-BN-AA1/Dox lipo-
somes on PC-3 prostate cancer cells was also assessed, 
and compared to the behavior of the previously studied 
DSPC/MonY-BN/Dox liposomes and to the underiva-
tized DSPC/Dox liposomes and to free doxorubicin. 
PC-3 cells were exposed to liposome formulations (100 
µL) containing 500 or 1500 ng of lipids and 100 or 300 ng 
of Dox, respectively, or to free doxorubicin, for 8 h, and 
the cell viability was measured by MTS assays (Figure 4). 
Incubation of cells with both targeted doxorubicin lipo-
somes showed significantly lower cell survival compared 
to DSPC/Dox treated cells, in the presence of 100 ng/mL 
and 300 ng/mL drug amounts. The increased potency 
of targeted liposome with respect to DSPC/Dox can be 
fully attributed to Dox because control experiments with 
empty liposome had no significant effect on cell viability 
(data already reported) (Accardo et al., 2012). The two 
peptide derivatized liposomal systems, DSPC/MonY-
BN-AA1/Dox and DSPC/MonY-BN/Dox present a simi-
lar cytotoxic activity, as expected by the similar binding 
properties of the respective labeled DOTA-peptides.
In vivo studies
In vivo studies on the therapeutic efficacy of DSPC/MonY-
BN-AA1/Dox targeted liposomes in comparison to 
already described (Accardo et al., 2012) DSPC/MonY-BN/
Dox targeted liposomes, to DSPC/Dox liposomes and to 
saline were performed in PC-3 xenograft bearing mice. 
In mice treated with DSPC/MonY-BN/Dox and DSPC/
MonY-BN-AA1/Dox targeted liposome formulations 
tumor volume was significantly reduced, compared to 
saline treated mice, at 15 and 19 days post treatment 
(Figure 5A). Conversely, in mice treated with DSPC/Dox 
tumor volume was not significantly different from saline 
group, at any time point considered.
For the new studied formulation, DSPC/MonY-
BN-AA1/Dox, the maximum effect was observed 19 
days after treatment (tumor growth inhibition was 43% 
compared to DSPC/Dox liposomes, and 59% compared 
to saline group, Figure 5A). It is likely that tumor growth 
inhibition observed in DSPC/MonY-BN-AA1/Dox and 
Table 2. Liposome characteristics. 
Formulations
Liposome 
diameter (nm) 
± S.D. P.I. ± S.D. ζ (mV)
DSPC 161.4 ± 0.10 0.09 ± 0.01 −6.7
DSPC/MonY-BN-AA1 136.3 ± 42.4 0.20 ± 0.05 −12.8
DSPC/MonY-BN-AA1/
DOX
153.7 ± 35.4 0.13 ± 0.08 −12.0
Figure 4. (A) Binding assays of DSPC/MonY-BN, DSPC/MonY-
BN-AA1 and DSPC/(C18)
2
DTPA 111In-radiolabeled liposomes on 
PC-3 cell line overexpressing the GRP at 37°C and 4°C at 1 h; (B) 
Results of cytotoxicity studies. Human prostatic cancer, PC-3, cells 
were treated with free Dox or with liposomal Dox compositions: 
DSPC/MonY-BN-AA1/Dox, and DSPC/Dox; at 100 or 300 ng of 
Dox. Control experiments were performed using empty liposomes 
of DSPC/MonY-BN-AA1 at the same experimental conditions. 
Cytotoxicity of DSPC/MonY-BN/Dox is also reported for 
comparison. Data are expressed as percent of control. Each value is 
the mean ± SEM of three experiments performed in triplicate.
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DSPC/MonY-BN/Dox groups, over considered time 
interval may be due to different kinetics of the targeted 
liposomes compared to DSPC/Dox group. The hypoth-
esis is that targeted liposomes, by binding to their spe-
cific receptors within the tumor, allow to achieve high 
drug concentrations into the tissue for a longer time than 
liposomes lacking the targeting ability. This hypothesis 
needs to be further investigated and confirmed. Body 
weight was also evaluated for all groups as a measure of 
therapeutic effect. As shown in Figure 5B, animals treated 
with both targeted liposomal formulations did not show 
the same degree of progressive body weight loss as con-
trol animals. In these animals, treated with only DSPC/
Dox liposomes, the exponential tumor growth observed 
starting about 10 days following treatment was paralleled 
by a clear reduction in body weight.
conclusions
The newly developed DSPC/MonY-BN-AA1/Dox nano-
vectors confirm the ability to selectively target and pro-
vide therapeutic efficacy in PC-3 cells and PC-3 xenograft 
bearing mice previously obtained with DSPC/MonY-BN/
Dox. Although the two compounds yield very similar 
results in the in vitro and in vivo assays presented, the lack 
of receptor activation and possible acute biological side 
effects provided by using the AA1 antagonist sequence 
should provide safer working conditions for further 
development of this class of drug delivery vehicles.
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